Chunxia Qiao

473 total citations
53 papers, 371 citations indexed

About

Chunxia Qiao is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Chunxia Qiao has authored 53 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 19 papers in Oncology and 18 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Chunxia Qiao's work include Monoclonal and Polyclonal Antibodies Research (17 papers), HER2/EGFR in Cancer Research (7 papers) and Glycosylation and Glycoproteins Research (6 papers). Chunxia Qiao is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (17 papers), HER2/EGFR in Cancer Research (7 papers) and Glycosylation and Glycoproteins Research (6 papers). Chunxia Qiao collaborates with scholars based in China, Czechia and Taiwan. Chunxia Qiao's co-authors include Jiannan Feng, Bing Shen, Ming Lv, Jing Wang, Longlong Luo, Jing Geng, Jiyan Zhang, Xinying Li, Guojiang Chen and Xinying Li and has published in prestigious journals such as The Journal of Immunology, Journal of Virology and Scientific Reports.

In The Last Decade

Chunxia Qiao

48 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chunxia Qiao China 12 162 96 86 80 39 53 371
Yoshinari Watanabe Japan 14 254 1.6× 179 1.9× 98 1.1× 34 0.4× 39 1.0× 24 595
Simone L. Popp Germany 8 133 0.8× 212 2.2× 137 1.6× 47 0.6× 17 0.4× 13 407
Geneviève Laroche Canada 16 374 2.3× 59 0.6× 27 0.3× 40 0.5× 19 0.5× 27 544
Erin L. Filbert United States 7 284 1.8× 172 1.8× 84 1.0× 19 0.2× 32 0.8× 19 526
Arup K. Bag United States 10 273 1.7× 135 1.4× 148 1.7× 15 0.2× 72 1.8× 18 481
Yehudi Bloch Belgium 12 216 1.3× 205 2.1× 99 1.2× 44 0.6× 47 1.2× 19 524
Laura Calvo‐Barreiro Spain 13 387 2.4× 80 0.8× 52 0.6× 41 0.5× 13 0.3× 28 556
Eun‐Wie Cho South Korea 14 226 1.4× 92 1.0× 73 0.8× 39 0.5× 81 2.1× 26 423
Byron J. Aguilar United States 12 232 1.4× 68 0.7× 66 0.8× 40 0.5× 39 1.0× 20 390

Countries citing papers authored by Chunxia Qiao

Since Specialization
Citations

This map shows the geographic impact of Chunxia Qiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunxia Qiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunxia Qiao more than expected).

Fields of papers citing papers by Chunxia Qiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chunxia Qiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunxia Qiao. The network helps show where Chunxia Qiao may publish in the future.

Co-authorship network of co-authors of Chunxia Qiao

This figure shows the co-authorship network connecting the top 25 collaborators of Chunxia Qiao. A scholar is included among the top collaborators of Chunxia Qiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chunxia Qiao. Chunxia Qiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Jie, Ning Shi, Xuechen Yang, et al.. (2025). Comparative evaluation of bispecific antibody formats targeting PD-1 and LAG-3 for dual checkpoint blockade in cancer immunotherapy. Biomedicine & Pharmacotherapy. 192. 118583–118583.
2.
Zheng, Hang, Yuting Zhang, Haiyan Wu, et al.. (2025). Improved acid-driven inhibition of effector T cell function by a pHLIP variant-conjugated PD-L1. Scientific Reports. 15(1). 13422–13422. 1 indexed citations
3.
Wang, Zhihong, Hui Dong, Ning Shi, et al.. (2024). Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2. Advanced Science. 11(45). e2402975–e2402975. 3 indexed citations
4.
Zhang, Yuting, Min Zhang, Xinwei Wang, et al.. (2023). A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus. eLife. 12. 3 indexed citations
5.
Hu, Naijing, Yingjun Liu, Longlong Luo, et al.. (2023). Functional epitopes and neutralizing antibodies of vaccinia virus. Frontiers in Microbiology. 14. 1255935–1255935. 2 indexed citations
6.
Wang, Chuanjie, Zhaolin Sun, Ming Wang, et al.. (2022). Novel CRISPR/Cas9-mediated knockout of LIG4 increases efficiency of site-specific integration in Chinese hamster ovary cell line. Biotechnology Letters. 44(9). 1063–1072. 5 indexed citations
7.
Sun, Ying, Min Zhang, Xinwei Wang, et al.. (2021). pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition. Frontiers in Immunology. 12. 794226–794226. 4 indexed citations
9.
Hu, Naijing, Chunxia Qiao, Jing Wang, et al.. (2021). Identification of a novel protective human monoclonal antibody, LXY8, that targets the key neutralizing epitopes of staphylococcal enterotoxin B. Biochemical and Biophysical Research Communications. 549. 120–127. 11 indexed citations
10.
Duan, Yanting, Longlong Luo, Chunxia Qiao, et al.. (2019). A novel human anti‐AXL monoclonal antibody attenuates tumour cell migration. Scandinavian Journal of Immunology. 90(2). e12777–e12777. 23 indexed citations
11.
Wen, Yan, et al.. (2019). Immunoregenerative effects of the bionically cultured Sanghuang mushrooms (Inonotus sanghuagn) on the immunodeficient mice. Journal of Ethnopharmacology. 245. 112047–112047. 20 indexed citations
12.
13.
Wang, Qingyang, Jingyang Wang, Junxia Cao, et al.. (2015). RACK1 antagonizes TNF-α-induced cell death by promoting p38 activation. Scientific Reports. 5(1). 14298–14298. 10 indexed citations
14.
Wang, Wei, Yan Zhang, Ming Lv, et al.. (2014). Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3. Journal of Ovarian Research. 7(1). 103–103. 7 indexed citations
15.
Yang, Jing, Qun Wang, Chunxia Qiao, et al.. (2014). Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60. Cellular and Molecular Immunology. 11(3). 285–293. 22 indexed citations
16.
Luo, Longlong, Qun Luo, Leiming Guo, et al.. (2013). Structure-based affinity maturation of a chimeric anti-ricin antibody C4C13. Journal of Biomolecular Structure and Dynamics. 32(3). 416–423. 6 indexed citations
17.
Hu, Yi, Chunxia Qiao, Ming Lv, et al.. (2012). Arg9 facilitates the translocation and downstream signal inhibition of an anti-HER2 single chain antibody. BMC Research Notes. 5(1). 336–336. 3 indexed citations
18.
Qiao, Chunxia, Ming Lv, Lin Zhou, et al.. (2012). Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation. BMC Immunology. 13(1). 40–40. 1 indexed citations
19.
Wang, Jing, Ming Lv, Qingyang Wang, et al.. (2010). Defective anchoring of JNK1 in the cytoplasm by MKK7 in Jurkat cells is associated with resistance to Fas-mediated apoptosis. Molecular Biology of the Cell. 22(1). 117–127. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026